Allogene Therapeutics, which tackles cancer by altering immune cells to make them fight the disease better, has raised $288m in an IPO on Nasdaq. Alex Lash contributed to this report Image of T cell by Flickr user NIAID via The firm is one of a number tackling cancer with chimeric antigen receptor (CAR-T) therapies. It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 16 other preclinical CAR-T products. It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies. In March it announced that its first human trial was under way at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.
Allogene Therapeutics, which tackles cancer by altering immune cells to make them fight the disease better, has raised $288m in an IPO on Nasdaq. The firm is one of a number tackling cancer with chimeric antigen receptor (CAR-T) therapies. It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 16 other preclinical CAR-T products. It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies. In March it announced that its first human trial was under way at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.